Company

ReviR Therapeutics, Inc.

ReviR Therapeutics develops small-molecule drugs that target RNA.

About

Founded in 2021 in Shenzhen, ReviR Therapeutics develops small-molecule drugs targeting RNA for tumors and rare diseases, using its VoyageR AI platform. Its CEO, Peng Yue, previously led computational biology at AbbVie/Stemcentrx. The company raised USD 30 million in Series A funding in July 2024. It planned to advance programs for Huntington's disease and amyotrophic lateral sclerosis.

3Funding rounds

7Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in